BIOGEN INC. - COMMON STOCK

118,17

09-мая-25 15:45:00

15 мин. задержка

Акции

-0,22

-0,19%

Сегодняшний диапазон

118,05 - 120,11

ISIN

N/A

Источник

NASDAQ

Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025

28 окт 2024 07:30:00 Источник Nasdaq GlobeNewswire
Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024

26 окт 2024 19:15:00 Источник Nasdaq GlobeNewswire
NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

25 окт 2024 15:10:18 Источник NetDania Notify
Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference

24 окт 2024 06:30:00 Источник Nasdaq GlobeNewswire
Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024

22 окт 2024 06:30:00 Источник Nasdaq GlobeNewswire
Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients

09 окт 2024 06:30:00 Источник Nasdaq GlobeNewswire
NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

08 окт 2024 09:05:33 Источник NetDania Notify
New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA

08 окт 2024 06:30:00 Источник Nasdaq GlobeNewswire
NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

07 окт 2024 11:25:18 Источник NetDania Notify
NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

03 окт 2024 08:45:05 Источник NetDania Notify
NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

02 окт 2024 14:08:16 Источник NetDania Notify
NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

25 сен 2024 15:06:38 Источник NetDania Notify
UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

24 сен 2024 00:00:00 Источник Nasdaq GlobeNewswire
Biogen Board Appoints Two New Independent Directors

12 сен 2024 06:30:00 Источник Nasdaq GlobeNewswire
Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA

04 сен 2024 06:30:34 Источник Nasdaq GlobeNewswire
New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alzheimer’s Association International Conference (AAIC) 2024

30 июл 2024 16:15:17 Источник Nasdaq GlobeNewswire
Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease

30 июл 2024 06:30:00 Источник Nasdaq GlobeNewswire
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

26 июл 2024 06:20:38 Источник Nasdaq GlobeNewswire
Biogen Completes Acquisition of Human Immunology Biosciences

02 июл 2024 08:16:51 Источник Nasdaq GlobeNewswire
“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China

27 июн 2024 18:39:36 Источник Nasdaq GlobeNewswire

<<
<
1
2
3
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.